Answers are grounded in this paper and cite their sources.
Children, although at lower risk of poor outcomes from COVID-19 relative to adults, still stand to benefit from therapeutic interventions. Understanding of COVID-19 clinical presentation and prognosis in children is essential to optimize therapeutic trials design. This perspective illustrates how to collectively accelerate pediatric COVID-19 therapeutic research and development, based on the experience of the Global Accelerator for Paediatric Formulations.
No takes yet. Share an insight, caveat, or question.
Morin et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: